ResMed Inc
RMD
Company Profile
Business description
ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.
Contact
9001 Spectrum Center Boulevard
San DiegoCA92123
USAT: +1 858 836-5000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
30 June 2027
Employees
11,370
ResMed Inc News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
stocks
Solid quarter for undervalued ASX listed share
Solid global sales and margin expansion are highlights from latest quarter.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.60 | 95.80 | -1.07% |
| CAC 40 | 8,144.83 | 2.00 | -0.02% |
| DAX 40 | 25,735.85 | 0.39 | -0.00% |
| Dow JONES (US) | 50,198.17 | 561.25 | -1.11% |
| FTSE 100 | 10,527.53 | 23.64 | -0.22% |
| HKSE | 22,841.62 | 453.13 | -1.95% |
| NASDAQ | 24,429.88 | 101.50 | 0.42% |
| Nikkei 225 | 59,444.21 | 419.93 | 0.71% |
| NZX 50 Index | 14,247.25 | 17.04 | -0.12% |
| S&P 500 | 7,323.63 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,730.40 | 91.40 | -1.04% |
| SSE Composite Index | 3,577.62 | 10.21 | -0.28% |